Search

Your search keyword '"Anderson TJ"' showing total 734 results
Start Over Author "Anderson TJ" Language english
734 results on '"Anderson TJ"'

1. Repurposing Metformin for the Treatment of Atrial Fibrillation: Current Insights

Author

Sarkar A, Fanous KI, Marei I, Ding H, Ladjimi M, MacDonald R, Hollenberg MD, Anderson TJ, Hill MA, and Triggle CR

Subjects
metformin, atrial fibrillation, ampk, hyperglycemia, hypoglycemia, cardiac metabolism, cardio-vascular protection, atrial remodeling, Diseases of the circulatory (Cardiovascular) system, RC666-701
Abstract

Aparajita Sarkar,1 Kareem Imad Fanous,1 Isra Marei,2 Hong Ding,2 Moncef Ladjimi,3 Ross MacDonald,4 Morley D Hollenberg,5 Todd J Anderson,6 Michael A Hill,7 Chris R Triggle2 1Department of Medical Education, Weill Cornell Medicine-Qatar, Doha, Qatar; 2Department of Pharmacology & Medical Education, Weill Cornell Medicine- Qatar, Doha, Qatar; 3Department of Biochemistry & Medical Education, Weill Cornell Medicine-Qatar, Doha, Qatar; 4Health Sciences Library, Weill Cornell Medicine-Qatar, Doha, Qatar; 5Department of Physiology & Pharmacology, and Department of Medicine, Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada; 6Department of Cardiac Sciences and Libin Cardiovascular Institute, Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada; 7Dalton Cardiovascular Research Center & Department of Medical Pharmacology & Physiology, School of Medicine, University of Missouri, Columbia, Missouri, USACorrespondence: Aparajita Sarkar; Chris R Triggle, Email aps4003@qatar-med.cornell.edu; cht2011@qatar-med.cornell.eduAbstract: Metformin is an orally effective anti-hyperglycemic drug that despite being introduced over 60 years ago is still utilized by an estimated 120 to 150 million people worldwide for the treatment of type 2 diabetes (T2D). Metformin is used off-label for the treatment of polycystic ovary syndrome (PCOS) and for pre-diabetes and weight loss. Metformin is a safe, inexpensive drug with side effects mostly limited to gastrointestinal issues. Prospective clinical data from the United Kingdom Prospective Diabetes Study (UKPDS), completed in 1998, demonstrated that metformin not only has excellent therapeutic efficacy as an anti-diabetes drug but also that good glycemic control reduced the risk of micro- and macro-vascular complications, especially in obese patients and thereby reduced the risk of diabetes-associated cardiovascular disease (CVD). Based on a long history of clinical use and an excellent safety record metformin has been investigated to be repurposed for numerous other diseases including as an anti-aging agent, Alzheimer’s disease and other dementias, cancer, COVID-19 and also atrial fibrillation (AF). AF is the most frequently diagnosed cardiac arrythmia and its prevalence is increasing globally as the population ages. The argument for repurposing metformin for AF is based on a combination of retrospective clinical data and in vivo and in vitro pre-clinical laboratory studies. In this review, we critically evaluate the evidence that metformin has cardioprotective actions and assess whether the clinical and pre-clinical evidence support the use of metformin to reduce the risk and treat AF. Keywords: metformin, atrial fibrillation, AMPK, hyperglycemia, hypoglycemia, cardiac metabolism, cardiovascular protection, atrial remodeling

Published
2024

2. Cosmogenic production of Ar37 in the context of the LUX-ZEPLIN experiment

Author

Aalbers, J, Akerib, DS, Musalhi, AKA, Alder, F, Alsum, SK, Amarasinghe, CS, Ames, A, Anderson, TJ, Angelides, N, Araújo, HM, Armstrong, JE, Arthurs, M, Bai, X, Baker, A, Balajthy, J, Balashov, S, Bang, J, Bargemann, JW, Bauer, D, Baxter, A, Beattie, K, Bernard, EP, Bhatti, A, Biekert, A, Biesiadzinski, TP, Birch, HJ, Blockinger, GM, Bodnia, E, Boxer, B, Brew, CAJ, Brás, P, Burdin, S, Busenitz, JK, Buuck, M, Cabrita, R, Carmona-Benitez, MC, Cascella, M, Chan, C, Chawla, A, Chen, H, Chott, NI, Cole, A, Converse, MV, Cottle, A, Cox, G, Creaner, O, Cutter, JE, Dahl, CE, David, A, de Viveiros, L, Dobson, JEY, Druszkiewicz, E, Eriksen, SR, Fan, A, Fayer, S, Fearon, NM, Fiorucci, S, Flaecher, H, Fraser, ED, Fruth, T, Gaitskell, RJ, Genovesi, J, Ghag, C, Gibson, E, Gilchriese, MGD, Gokhale, S, van der Grinten, MGD, Gwilliam, CB, Hall, CR, Haselschwardt, SJ, Hertel, SA, Horn, M, Huang, DQ, Hunt, D, Ignarra, CM, Jahangir, O, James, RS, Ji, W, Johnson, J, Kaboth, AC, Kamaha, AC, Kamdin, K, Khaitan, D, Khazov, A, Khurana, I, Kodroff, D, Korley, L, Korolkova, EV, Kraus, H, Kravitz, S, Kreczko, L, Kudryavtsev, VA, Leason, EA, Leonard, DS, Lesko, KT, Levy, C, Lee, J, Lin, J, Lindote, A, Linehan, R, Lippincott, WH, Liu, X, Lopes, MI, Asamar, EL, Lopez-Paredes, B, Lorenzon, W, Luitz, S, Majewski, PA, Manalaysay, A, Manenti, L, Mannino, RL, Marangou, N, McCarthy, ME, McKinsey, DN, McLaughlin, J, Miller, EH, Mizrachi, E, Monte, A, Monzani, ME, Morad, JA, Mendoza, JDM, Morrison, E, Mount, BJ, St. J. Murphy, A, Naim, D, Naylor, A, Nedlik, C, Nelson, HN, Neves, F, Nikoleyczik, JA, Nilima, A, Olcina, I, Oliver-Mallory, K, Pal, S, Palladino, KJ, Palmer, J, Parveen, N, Patton, SJ, Pease, EK, Penning, B, Pereira, G, Perry, E, Pershing, J, Piepke, A, Porzio, D, Qie, Y, Reichenbacher, J, Rhyne, CA, Richards, A, Riffard, Q, Rischbieter, GRC, Rosero, R, Rossiter, P, Rushton, T, Santone, D, Sazzad, ABMR, Schnee, RW, Scovell, PR, Shaw, S, Shutt, TA, Silk, JJ, Silva, C, Sinev, G, Smith, R, Solmaz, M, Solovov, VN, Sorensen, P, Soria, J, Stancu, I, Stevens, A, Stifter, K, Suerfu, B, Sumner, TJ, Swanson, N, Szydagis, M, Taylor, WC, Taylor, R, Temples, DJ, Terman, PA, Tiedt, DR, Timalsina, M, To, WH, Tong, Z, Tovey, DR, Trask, M, Tripathi, M, Tronstad, DR, Turner, W, Utku, U, Vaitkus, A, Wang, B, Wang, Y, Wang, JJ, Wang, W, Watson, JR, Webb, RC, White, RG, Whitis, TJ, Williams, M, Wolfs, FLH, Woodford, S, Woodward, D, Wright, CJ, Xia, Q, Xiang, X, Xu, J, and Yeh, M

Published
2022

3. Cosmogenic production of 37 Ar in the context of the LUX-ZEPLIN experiment

Author

Aalbers, J, Akerib, DS, Al Musalhi, AK, Alder, F, Alsum, SK, Amarasinghe, CS, Ames, A, Anderson, TJ, Angelides, N, Araújo, HM, Armstrong, JE, Arthurs, M, Bai, X, Baker, A, Balajthy, J, Balashov, S, Bang, J, Bargemann, JW, Bauer, D, Baxter, A, Beattie, K, Bernard, EP, Bhatti, A, Biekert, A, Biesiadzinski, TP, Birch, HJ, Blockinger, GM, Bodnia, E, Boxer, B, Brew, CAJ, Brás, P, Burdin, S, Busenitz, JK, Buuck, M, Cabrita, R, Carmona-Benitez, MC, Cascella, M, Chan, C, Chawla, A, Chen, H, Chott, NI, Cole, A, Converse, MV, Cottle, A, Cox, G, Creaner, O, Cutter, JE, Dahl, CE, David, A, De Viveiros, L, Dobson, JEY, Druszkiewicz, E, Eriksen, SR, Fan, A, Fayer, S, Fearon, NM, Fiorucci, S, Flaecher, H, Fraser, ED, Fruth, T, Gaitskell, RJ, Genovesi, J, Ghag, C, Gibson, E, Gilchriese, MGD, Gokhale, S, Van der Grinten, MGD, Gwilliam, CB, Hall, CR, Haselschwardt, SJ, Hertel, SA, Horn, M, Huang, DQ, Hunt, D, Ignarra, CM, Jahangir, O, James, RS, Ji, W, Johnson, J, Kaboth, AC, Kamaha, AC, Kamdin, K, Khaitan, D, Khazov, A, Khurana, I, Kodroff, D, Korley, L, Korolkova, EV, Kraus, H, Kravitz, S, Kreczko, L, Kudryavtsev, VA, Leason, EA, Leonard, DS, Lesko, KT, Levy, C, Lee, J, Lin, J, Lindote, A, Linehan, R, Lippincott, WH, Liu, X, Lopes, MI, Lopez Asamar, E, Lopez-Paredes, B, Lorenzon, W, Luitz, S, Majewski, PA, Manalaysay, A, Manenti, L, Mannino, RL, Marangou, N, McCarthy, ME, McKinsey, DN, McLaughlin, J, Miller, EH, Mizrachi, E, Monte, A, Monzani, ME, Morad, JA, Morales Mendoza, JD, Morrison, E, Mount, BJ, Murphy, ASJ, Naim, D, Naylor, A, Nedlik, C, Nelson, HN, Neves, F, Nikoleyczik, JA, Nilima, A, Olcina, I, Oliver-Mallory, K, Pal, S, Palladino, KJ, Palmer, J, Parveen, N, Patton, SJ, Pease, EK, Penning, B, Pereira, G, Perry, E, Pershing, J, Piepke, A, Porzio, D, Qie, Y, Reichenbacher, J, Rhyne, CA, Richards, A, Riffard, Q, Rischbieter, GRC, Rosero, R, Rossiter, P, Rushton, T, Santone, D, Sazzad, ABMR, Schnee, RW, Scovell, PR, Shaw, S, Shutt, TA, Silk, JJ, Silva, C, Sinev, G, Smith, R, Solmaz, M, Solovov, VN, Sorensen, P, Soria, J, Stancu, I, Stevens, A, Stifter, K, Suerfu, B, Sumner, TJ, Swanson, N, Szydagis, M, Taylor, WC, Taylor, R, Temples, DJ, Terman, PA, Tiedt, DR, Timalsina, M, To, WH, Tong, Z, Tovey, DR, Trask, M, Tripathi, M, Tronstad, DR, Turner, W, Utku, U, Vaitkus, A, Wang, B, Wang, Y, Wang, JJ, Wang, W, Watson, JR, Webb, RC, White, RG, Whitis, TJ, Williams, M, Wolfs, FLH, Woodford, S, Woodward, D, Wright, CJ, Xia, Q, Xiang, X, Xu, J, and Yeh, M

Subjects
hep-ex, astro-ph.CO, hep-ph, astro-ph.IM
Abstract

We estimate the amount of 37 Ar produced in natural xenon via cosmic-ray-induced spallation, an inevitable consequence of the transportation and storage of xenon on the Earth’s surface. We then calculate the resulting 37 Ar concentration in a 10-tonne payload (similar to that of the LUX-ZEPLIN experiment) assuming a representative schedule of xenon purification, storage, and delivery to the underground facility. Using the spallation model by Silberberg and Tsao, the sea-level production rate of 37 Ar in natural xenon is estimated to be 0.024 atoms / kg / day . Assuming the xenon is successively purified to remove radioactive contaminants in 1-tonne batches at a rate of 1 tonne / month , the average 37 Ar activity after 10 tons are purified and transported underground is 0.058 − 0.090 μ Bq / kg , depending on the degree of argon removal during above-ground purification. Such cosmogenic 37 Ar will appear as a noticeable background in the early science data, while decaying with a 35-day half-life. This newly noticed production mechanism of 37 Ar should be considered when planning for future liquid-xenon-based experiments.

Published
2022

4. Projected sensitivity of the LUX-ZEPLIN experiment to the two-neutrino and neutrinoless double β decays of 134Xe

Author

Akerib, DS, Al Musalhi, AK, Alsum, SK, Amarasinghe, CS, Ames, A, Anderson, TJ, Angelides, N, Araújo, HM, Armstrong, JE, Arthurs, M, Bai, X, Balajthy, J, Balashov, S, Bang, J, Bargemann, JW, Bauer, D, Baxter, A, Beltrame, P, Bernard, EP, Bernstein, A, Bhatti, A, Biekert, A, Biesiadzinski, TP, Birch, HJ, Blockinger, GM, Bodnia, E, Boxer, B, Brew, CAJ, Brás, P, Burdin, S, Busenitz, JK, Buuck, M, Cabrita, R, Carmona-Benitez, MC, Cascella, M, Chan, C, Chott, NI, Cole, A, Converse, MV, Cottle, A, Cox, G, Creaner, O, Cutter, JE, Dahl, CE, de Viveiros, L, Dobson, JEY, Druszkiewicz, E, Eriksen, SR, Fan, A, Fayer, S, Fearon, NM, Fiorucci, S, Flaecher, H, Fraser, ED, Fruth, T, Gaitskell, RJ, Genovesi, J, Ghag, C, Gibson, E, Gokhale, S, van der Grinten, MGD, Gwilliam, CB, Hall, CR, Haselschwardt, SJ, Hertel, SA, Horn, M, Huang, DQ, gnarra, MCI, Jahangir, O, James, RS, Ji, W, Johnson, J, Kaboth, AC, Kamaha, AC, Kamdin, K, Kazkaz, K, Khaitan, D, Khazov, A, Khurana, I, Kodroff, D, Korley, L, Korolkova, EV, Kraus, H, Kravitz, S, Kreczko, L, Krikler, B, Kudryavtsev, VA, Leason, EA, Lee, J, Leonard, DS, Lesko, KT, Levy, C, Liao, J, Lin, J, Lindote, A, Linehan, R, Lippincott, WH, Liu, X, Lopes, MI, López Asamar, E, López Paredes, B, Lorenzon, W, Luitz, S, Majewski, PA, Manalaysay, A, Manenti, L, Mannino, RL, Marangou, N, McCarthy, ME, McKinsey, DN, McLaughlin, J, Miller, EH, Mizrachi, E, Monte, A, Monzani, ME, Morad, JA, Morales Mendoza, JD, Morrison, E, Mount, BJ, Murphy, ASJ, Naim, D, Naylor, A, Nedlik, C, Nelson, HN, Neves, F, Nikoleyczik, JA, Nilima, A, Olcina, I, Oliver-Mallory, KC, Pal, S, Palladino, KJ, Palmer, J, Patton, S, Parveen, N, Pease, EK, Penning, B, Pereira, G, Piepke, A, Qie, Y, Reichenbacher, J, Rhyne, CA, Richards, A, Riffard, Q, Rischbieter, GRC, Rosero, R, Rossiter, P, Santone, D, Sazzad, ABMR, Schnee, RW, Scovell, PR, Shaw, S, Shutt, TA, Silk, JJ, Silva, C, Smith, R, Solmaz, M, Solovov, VN, Sorensen, P, Soria, J, Stancu, I, Stevens, A, Stifter, K, Suerfu, B, Sumner, TJ, Swanson, N, Szydagis, M, Taylor, WC, Taylor, R, Temples, DJ, Terman, PA, Tiedt, DR, Timalsina, M, To, WH, Tovey, DR, Tripathi, M, Tronstad, DR, Turner, W, Utku, U, Vaitkus, A, Wang, B, Wang, JJ, Wang, W, Watson, JR, Webb, RC, White, RG, Whitis, TJ, Williams, M, Wolfs, FLH, Woodward, D, Wright, CJ, Xiang, X, Xu, J, Yeh, M, and Zarzhitsky, P

Published
2021

5. Projected sensitivity of the LUX-ZEPLIN experiment to the two-neutrino and neutrinoless double β decays of Xe134

Author

Akerib, DS, Al Musalhi, AK, Alsum, SK, Amarasinghe, CS, Ames, A, Anderson, TJ, Angelides, N, Araújo, HM, Armstrong, JE, Arthurs, M, Bai, X, Balajthy, J, Balashov, S, Bang, J, Bargemann, JW, Bauer, D, Baxter, A, Beltrame, P, Bernard, EP, Bernstein, A, Bhatti, A, Biekert, A, Biesiadzinski, TP, Birch, HJ, Blockinger, GM, Bodnia, E, Boxer, B, Brew, CAJ, Brás, P, Burdin, S, Busenitz, JK, Buuck, M, Cabrita, R, Carmona-Benitez, MC, Cascella, M, Chan, C, Chott, NI, Cole, A, Converse, MV, Cottle, A, Cox, G, Creaner, O, Cutter, JE, Dahl, CE, De Viveiros, L, Dobson, JEY, Druszkiewicz, E, Eriksen, SR, Fan, A, Fayer, S, Fearon, NM, Fiorucci, S, Flaecher, H, Fraser, ED, Fruth, T, Gaitskell, RJ, Genovesi, J, Ghag, C, Gibson, E, Gokhale, S, Van der Grinten, MGD, Gwilliam, CB, Hall, CR, Haselschwardt, SJ, Hertel, SA, Horn, M, Huang, DQ, Gnarra, MCI, Jahangir, O, James, RS, Ji, W, Johnson, J, Kaboth, AC, Kamaha, AC, Kamdin, K, Kazkaz, K, Khaitan, D, Khazov, A, Khurana, I, Kodroff, D, Korley, L, Korolkova, EV, Kraus, H, Kravitz, S, Kreczko, L, Krikler, B, Kudryavtsev, VA, Leason, EA, Lee, J, Leonard, DS, Lesko, KT, Levy, C, Liao, J, Lin, J, Lindote, A, Linehan, R, Lippincott, WH, Liu, X, Lopes, MI, López Asamar, E, López Paredes, B, Lorenzon, W, Luitz, S, Majewski, PA, Manalaysay, A, Manenti, L, Mannino, RL, Marangou, N, McCarthy, ME, McKinsey, DN, McLaughlin, J, Miller, EH, Mizrachi, E, Monte, A, Monzani, ME, Morad, JA, Morales Mendoza, JD, Morrison, E, Mount, BJ, Murphy, ASJ, Naim, D, Naylor, A, Nedlik, C, Nelson, HN, Neves, F, Nikoleyczik, JA, Nilima, A, Olcina, I, Oliver-Mallory, KC, Pal, S, Palladino, KJ, Palmer, J, Patton, S, Parveen, N, Pease, EK, Penning, B, Pereira, G, Piepke, A, Qie, Y, Reichenbacher, J, Rhyne, CA, Richards, A, Riffard, Q, Rischbieter, GRC, Rosero, R, Rossiter, P, Santone, D, Sazzad, ABMR, Schnee, RW, Scovell, PR, Shaw, S, Shutt, TA, Silk, JJ, Silva, C, Smith, R, Solmaz, M, Solovov, VN, Sorensen, P, Soria, J, Stancu, I, Stevens, A, Stifter, K, Suerfu, B, Sumner, TJ, Swanson, N, Szydagis, M, Taylor, WC, Taylor, R, Temples, DJ, Terman, PA, Tiedt, DR, Timalsina, M, To, WH, Tovey, DR, Tripathi, M, Tronstad, DR, Turner, W, Utku, U, Vaitkus, A, Wang, B, Wang, JJ, Wang, W, Watson, JR, Webb, RC, White, RG, Whitis, TJ, Williams, M, Wolfs, FLH, Woodward, D, Wright, CJ, Xiang, X, Xu, J, Yeh, M, and Zarzhitsky, P

Subjects
nucl-ex, physics.ins-det
Abstract

The projected sensitivity of the LUX-ZEPLIN (LZ) experiment to two-neutrino and neutrinoless double β decay of 134 Xe is presented. LZ is a 10-tonne xenon time-projection chamber optimized for the detection of dark matter particles and is expected to start operating in 2021 at Sanford Underground Research Facility, USA. Its large mass of natural xenon provides an exceptional opportunity to search for the double β decay of 134 Xe , for which xenon detectors enriched in 136 Xe are less effective. For the two-neutrino decay mode, LZ is predicted to exclude values of the half-life up to 1.7 × 10 24 years at 90% confidence level (CL) and has a three-sigma observation potential of 8.7 × 10 23 years, approaching the predictions of nuclear models. For the neutrinoless decay mode LZ, is projected to exclude values of the half-life up to 7.3 × 10 24 years at 90% CL.

Published
2021

6. Projected sensitivities of the LUX-ZEPLIN experiment to new physics via low-energy electron recoils

Author

Collaboration, TLZ, Akerib, DS, Musalhi, AKA, Alsum, SK, Amarasinghe, CS, Ames, A, Anderson, TJ, Angelides, N, Araújo, HM, Armstrong, JE, Arthurs, M, Bai, X, Balajthy, J, Balashov, S, Bang, J, Bargemann, JW, Bauer, D, Baxter, A, Beltrame, P, Bernard, EP, Bernstein, A, Bhatti, A, Biekert, A, Biesiadzinski, TP, Birch, HJ, Blockinger, GM, Boxer, B, Brew, CAJ, Brás, P, Burdin, S, Busenitz, JK, Buuck, M, Cabrita, R, Carmona-Benitez, MC, Cascella, M, Chan, C, Chott, NI, Cole, A, Converse, MV, Cottle, A, Cox, G, Creaner, O, Cutter, JE, Dahl, CE, Viveiros, LD, Dobson, JEY, Druszkiewicz, E, Eriksen, SR, Fan, A, Fayer, S, Fearon, NM, Fiorucci, S, Flaecher, H, Fraser, ED, Fruth, T, Gaitskell, RJ, Genovesi, J, Ghag, C, Gibson, E, Gokhale, S, Grinten, MGDVD, Gwilliam, CB, Hall, CR, Hardy, CA, Haselschwardt, SJ, Hertel, SA, Horn, M, Huang, DQ, Ignarra, CM, Jahangir, O, James, RS, Ji, W, Johnson, J, Kaboth, AC, Kamaha, AC, Kamdin, K, Kazkaz, K, Khaitan, D, Khazov, A, Khurana, I, Kodroff, D, Korley, L, Korolkova, EV, Kraus, H, Kravitz, S, Kreczko, L, Krikler, B, Kudryavtsev, VA, Leason, EA, Lesko, KT, Levy, C, Li, J, Liao, J, Lin, J, Lindote, A, Linehan, R, Lippincott, WH, Liu, X, Lopes, MI, Asamar, EL, Paredes, BL, Lorenzon, W, Luitz, S, Majewski, PA, Manalaysay, A, Manenti, L, Mannino, RL, Marangou, N, McCarthy, ME, McKinsey, DN, McLaughlin, J, Miller, EH, Mizrachi, E, Monte, A, Monzani, ME, Morad, JA, Mendoza, JDM, Morrison, E, Mount, BJ, Murphy, ASJ, Naim, D, Naylor, A, Nedlik, C, Nelson, HN, Neves, F, Nikoleyczik, JA, Nilima, A, Olcina, I, Oliver-Mallory, KC, Pal, S, Palladino, KJ, Palmer, J, Patton, S, Parveen, N, Pease, EK, Penning, B, Pereira, G, Piepke, A, Qie, Y, Reichenbacher, J, Rhyne, CA, Richards, A, Riffard, Q, Rischbieter, GRC, Rosero, R, Rossiter, P, Santone, D, Sazzad, ABMR, Schnee, RW, Scovell, PR, Shaw, S, Shutt, TA, Silk, JJ, Silva, C, Smith, R, Solmaz, M, Solovov, VN, Sorensen, P, Soria, J, Stancu, I, Stevens, A, Stifter, K, Suerfu, B, Sumner, TJ, Swanson, N, Szydagis, M, Taylor, WC, Taylor, R, Temples, DJ, Terman, PA, Tiedt, DR, Timalsina, M, To, WH, Tovey, DR, Tripathi, M, Tronstad, DR, Turner, W, Utku, U, Vaitkus, A, Wang, B, Wang, JJ, Wang, W, Watson, JR, Webb, RC, White, RG, Whitis, TJ, Williams, M, Wolfs, FLH, Woodward, D, Wright, CJ, Xiang, X, Xu, J, Yeh, M, and Zarzhitsky, P

Subjects
Physics::Instrumentation and Detectors
Abstract

LUX-ZEPLIN is a dark matter detector expected to obtain world-leading sensitivity to weakly-interacting massive particles interacting via nuclear recoils with a ∼7-tonne xenon target mass. This paper presents sensitivity projections to several low-energy signals of the complementary electron recoil signal type: 1) an effective neutrino magnetic moment, and 2) an effective neutrino millicharge, both for pp-chain solar neutrinos, 3) an axion flux generated by the Sun, 4) axionlike particles forming the Galactic dark matter, 5) hidden photons, 6) mirror dark matter, and 7) leptophilic dark matter. World-leading sensitivities are expected in each case, a result of the large 5.6 t 1000 d exposure and low expected rate of electron-recoil backgrounds in the

Published
2021

8. Projected sensitivity of the LUX-ZEPLIN experiment to the 0νββ decay of ¹³⁶Xe

Author

Akerib, DS, Akerlof, CW, Alqahtani, A, Alsum, SK, Anderson, TJ, Angelides, N, Araujo, HM, Armstrong, JE, Arthurs, M, Bai, X, Balajthy, J, Balashov, S, Bang, J, Baxter, A, Bensinger, J, Bernard, EP, Bernstein, A, Bhatti, A, Biekert, A, Biesiadzinski, TP, Birch, HJ, Boast, KE, Boxer, B, Bras, P, Buckley, JH, Bugaev, VV, Burdin, S, Busenitz, JK, Cabrita, R, Carels, C, Carlsmith, DL, Carmona-Benitez, MC, Cascella, M, Chan, C, Chott, NI, Cole, A, Cottle, A, Cutter, JE, Dahl, CE, de Viveiros, L, Dobson, JEY, Druszkiewicz, E, Edberg, TK, Eriksen, SR, Fan, A, Fiorucci, S, Flaecher, H, Fraser, ED, Fruth, T, Gaitskell, RJ, Genovesi, J, Ghag, C, Gibson, E, Gilchriese, MGD, Gokhale, S, van der Grinten, MGD, Hall, CR, Harrison, A, Haselschwardt, SJ, Hertel, SA, Hor, JY-K, Horn, M, Huang, DQ, Ignarra, CM, Jahangir, O, Ji, W, Johnson, J, Kaboth, AC, Kamaha, AC, Kamdin, K, Kazkaz, K, Khaitan, D, Khazov, A, Khurana, I, Kocher, CD, Korley, L, Korolkova, EV, Kras, J, Kraus, H, Kravitz, S, Kreczko, L, Krikler, B, Kudryavtsev, VA, Leason, EA, Lee, J, Leonard, DS, Lesko, KT, Levy, C, Li, J, Liao, J, Liao, F-T, Lin, J, Lindote, A, Linehan, R, Lippincott, WH, Liu, R, Liu, X, Loniewski, C, Lopes, MI, Paredes, B Lopez, Lorenzon, W, Luitz, S, Lyle, JM, Majewski, PA, Manalaysay, A, Manenti, L, Mannino, RL, Marangou, N, Marzioni, MF, McKinsey, DN, McLaughlin, J, Meng, Y, Miller, EH, Mizrachi, E, Monte, A, Monzani, ME, Morad, JA, Morrison, E, Mount, BJ, Murphy, A St J, Naim, D, Naylor, A, Nedlik, C, Nehrkorn, C, Nelson, HN, Neves, F, Nikoleyczik, JA, Nilima, A, O'Sullivan, K, Olcina, I, Oliver-Mallory, KC, Pal, S, Palladino, KJ, Palmer, J, Parveen, N, Pease, EK, Penning, B, Pereira, G, Pushkin, K, Reichenbacher, J, Rhyne, CA, Riffard, Q, Rischbieter, GRC, Rosero, R, Rossiter, P, Rutherford, G, Santone, D, Sazzad, ABMR, Schnee, RW, Schubnell, M, Seymour, D, Shaw, S, Shutt, TA, Silk, JJ, Silva, C, Smith, R, Solmaz, M, Solovov, VN, Sorensen, P, Stancu, I, Stevens, A, Stifter, K, Sumner, TJ, Swanson, N, Szydagis, M, Tan, M, Taylor, WC, Taylor, R, Temples, DJ, Terman, PA, Tiedt, DR, Timalsina, M, Tomas, A, Tripathi, M, Tronstad, DR, Turner, W, Tvrznikova, L, Utku, U, Vacheret, A, Vaitkus, A, Wang, JJ, Wang, W, Watson, JR, Webb, RC, White, RG, Whitis, TJ, Wolfs, FLH, Woodward, D, Xiang, X, Xu, J, Yeh, M, Zarzhitsky, P, and Collaboration, LUX-ZEPLINLZ

Published
2020

9. Projected sensitivity of the LUX-ZEPLIN experiment to the 0 ν β β decay of 136 Xe

Author

Akerib, DS, Akerlof, CW, Alqahtani, A, Alsum, SK, Anderson, TJ, Angelides, N, Araújo, HM, Armstrong, JE, Arthurs, M, Bai, X, Balajthy, J, Balashov, S, Bang, J, Baxter, A, Bensinger, J, Bernard, EP, Bernstein, A, Bhatti, A, Biekert, A, Biesiadzinski, TP, Birch, HJ, Boast, KE, Boxer, B, Brás, P, Buckley, JH, Bugaev, VV, Burdin, S, Busenitz, JK, Cabrita, R, Carels, C, Carlsmith, DL, Carmona-Benitez, MC, Cascella, M, Chan, C, Chott, NI, Cole, A, Cottle, A, Cutter, JE, Dahl, CE, De Viveiros, L, Dobson, JEY, Druszkiewicz, E, Edberg, TK, Eriksen, SR, Fan, A, Fiorucci, S, Flaecher, H, Fraser, ED, Fruth, T, Gaitskell, RJ, Genovesi, J, Ghag, C, Gibson, E, Gilchriese, MGD, Gokhale, S, Van der Grinten, MGD, Hall, CR, Harrison, A, Haselschwardt, SJ, Hertel, SA, Hor, JY-K, Horn, M, Huang, DQ, Ignarra, CM, Jahangir, O, Ji, W, Johnson, J, Kaboth, AC, Kamaha, AC, Kamdin, K, Kazkaz, K, Khaitan, D, Khazov, A, Khurana, I, Kocher, CD, Korley, L, Korolkova, EV, Kras, J, Kraus, H, Kravitz, S, Kreczko, L, Krikler, B, Kudryavtsev, VA, Leason, EA, Lee, J, Leonard, DS, Lesko, KT, Levy, C, Li, J, Liao, J, Liao, F-T, Lin, J, Lindote, A, Linehan, R, Lippincott, WH, Liu, R, Liu, X, Loniewski, C, Lopes, MI, López Paredes, B, Lorenzon, W, Luitz, S, Lyle, JM, Majewski, PA, Manalaysay, A, Manenti, L, Mannino, RL, Marangou, N, Marzioni, MF, McKinsey, DN, McLaughlin, J, Meng, Y, Miller, EH, Mizrachi, E, Monte, A, Monzani, ME, Morad, JA, Morrison, E, Mount, BJ, Murphy, ASJ, Naim, D, Naylor, A, Nedlik, C, Nehrkorn, C, Nelson, HN, Neves, F, Nikoleyczik, JA, Nilima, A, O'Sullivan, K, Olcina, I, Oliver-Mallory, KC, Pal, S, Palladino, KJ, Palmer, J, Parveen, N, Pease, EK, Penning, B, Pereira, G, Pushkin, K, Reichenbacher, J, Rhyne, CA, Riffard, Q, Rischbieter, GRC, Rosero, R, Rossiter, P, Rutherford, G, Santone, D, Sazzad, ABMR, Schnee, RW, Schubnell, M, Seymour, D, Shaw, S, Shutt, TA, Silk, JJ, Silva, C, Smith, R, Solmaz, M, Solovov, VN, Sorensen, P, Stancu, I, Stevens, A, Stifter, K, Sumner, TJ, Swanson, N, Szydagis, M, Tan, M, Taylor, WC, Taylor, R, Temples, DJ, Terman, PA, Tiedt, DR, Timalsina, M, Tomás, A, Tripathi, M, Tronstad, DR, Turner, W, Tvrznikova, L, Utku, U, Vacheret, A, Vaitkus, A, Wang, JJ, Wang, W, Watson, JR, Webb, RC, White, RG, Whitis, TJ, Wolfs, FLH, Woodward, D, Xiang, X, Xu, J, Yeh, M, and Zarzhitsky, P

Subjects
nucl-ex
Abstract

The LUX-ZEPLIN (LZ) experiment will enable a neutrinoless double β decay search in parallel to the main science goal of discovering dark matter particle interactions. We report the expected LZ sensitivity to 136 Xe neutrinoless double β decay, taking advantage of the significant ( > 600 kg) 136 Xe mass contained within the active volume of LZ without isotopic enrichment. After 1000 live-days, the median exclusion sensitivity to the half-life of 136 Xe is projected to be 1.06 × 10 26 years (90% confidence level), similar to existing constraints. We also report the expected sensitivity of a possible subsequent dedicated exposure using 90% enrichment with 136 Xe at 1.06 × 10 27 years.

Published
2020

10. Measures of benefit for breast screening from the pathology database for Scotland, 1991-2001

Author

Anderson, TJ, Davis, C, Alexander, FE, and Dobson, HM

Subjects
Clinical pathology -- Research -- Health aspects -- Methods, Cancer patients -- Health aspects -- Medical examination -- Demographic aspects -- Methods -- Research, Mammography -- Methods -- Research -- Health aspects, Breast cancer -- Health aspects -- Diagnosis -- Research, Medical screening -- Methods -- Health aspects -- Research, Health, Diagnosis, Medical examination, Research, Demographic aspects, Methods, Health aspects
Abstract

Aims: To examine pathology characteristics of breast cancers detected by mammography screening over 10 years in Scotland, and compare the nature of cancer yields after different levels of very small [...]

Published
2003

14. Impaired eye movements in post-concussion syndrome indicate suboptimal brain function beyond the influence of depression, malingering or intellectual ability

Author

Heitger, Marcus, Jones, RD, Macleod, AD, Snell, DL, Frampton, CM, and Anderson, TJ

Subjects
genetic structures
Abstract

Post-concussion syndrome (PCS) can affect up to 20%-30% of patients with mild closed head injury (mCHI), comprising incomplete recovery and debilitating persistence of post-concussional symptoms. Eye movements relate closely to the functional integrity of the injured brain and eye movement function is impaired post-acutely in mCHI. Here, we examined whether PCS patients continue to show disparities in eye movement function at 3-5 months following mCHI compared with patients with good recovery. We hypothesized that eye movements might provide sensitive and objective functional markers of ongoing cerebral impairment in PCS. We compared 36 PCS participants (adapted World Health Organization guidelines) and 36 individually matched controls (i.e. mCHI patients of similar injury severity but good recovery) on reflexive, anti- and self-paced saccades, memory-guided sequences and smooth pursuit. All completed neuropsychological testing and health status questionnaires. Mean time post-injury was 140 days in the PCS group and 163 days in the control group. The PCS group performed worse on anti-saccades, self-paced saccades, memory-guided sequences and smooth pursuit, suggesting problems in response inhibition, short-term spatial memory, motor-sequence programming, visuospatial processing and visual attention. This poorer oculomotor performance included several measures beyond conscious control, indicating that subcortical functionality in the PCS group was poorer than expected after mCHI. The PCS group had poorer neuropsychological function (memory, complex attention and executive function). Analysis of covariance showed oculomotor differences to be practically unaffected by group disparities in depression and estimated intellectual ability. Compared with neuropsychological tests, eye movements were more likely to be markedly impaired in PCS cases with high symptom load. Poorer eye movement function, and particularly poorer subcortical oculomotor function, correlated more with post-concussive symptom load and problems on activities of daily living whilst poorer neuropsychological function exhibited slightly better correlations with measures of mental health. Our findings that eye movement function in PCS does not follow the normal recovery path of eye movements after mCHI are indicative of ongoing cerebral impairment. Whilst oculomotor and neuropsychological tests partially overlapped in identifying impairment, eye movements showed additional dysfunction in motor/visuospatial areas, response inhibition, visual attention and subcortical function. Poorer subconscious oculomotor function in the PCS group supports the notion that PCS is not merely a psychological entity, but also has a biological substrate. Measurement of oculomotor function may be of value in PCS cases with a high symptom load but an otherwise unremarkable assessment profile. Routine oculomotor testing should be feasible in centres with existing access to this technology. ispartof: Brain vol:132 issue:10 pages:2850-2870 status: published

Published
2009

15. Saccade sequences as markers for cerebral dysfunction following mild closed head injury

Author

Heitger, Marcus, Anderson, TJ, Jones, RD, Hyönä, J, Munoz, DP, Heide, W, Radach, R, Hyönä, J., Munoz, D.P., Heide, W., and Radach, R.

Subjects
frontal eye field, posterior parietal cortex, supplementary motor area, memory-guided saccades, traumatic brain injury, transcranial magnetic stimulation, spatial working-memory, diffuse axonal injury, positron-emission-tomography, necrosis-factor-alpha
Abstract

Diffuse axonal injury caused by mild closed head injury (CHI) is likely to affect the neural networks concerned with the planning and execution of sequences of memory-guided saccades. Thirty subjects with mild CHI and thirty controls were tested on 2- and 3-step sequences of memory-guided saccades. CHI subjects showed more directional errors, larger position errors, and hypermetria of primary saccades and final eye position. No deficits were seen in temporal accuracy (timing and rhythm). These results suggest that computerized tests of saccade sequences can provide sensitive markers of cerebral dysfunction after mild CHI. ispartof: Progress in Brain Research vol:140 pages:433-448 ispartof: location:Turku, Finland status: published

Published
2002

17. Arterial spin labelling reveals an abnormal cerebral perfusion pattern in Parkinson's disease.

Author

Melzer TR, Watts R, Macaskill MR, Pearson JF, Rüeger S, Pitcher TL, Livingston L, Graham C, Keenan R, Shankaranarayanan A, Alsop DC, Dalrymple-Alford JC, Anderson TJ, Melzer, Tracy R, Watts, Richard, MacAskill, Michael R, Pearson, John F, Rüeger, Sina, Pitcher, Toni L, and Livingston, Leslie

Abstract

There is a need for objective imaging markers of Parkinson's disease status and progression. Positron emission tomography and single photon emission computed tomography studies have suggested patterns of abnormal cerebral perfusion in Parkinson's disease as potential functional biomarkers. This study aimed to identify an arterial spin labelling magnetic resonance-derived perfusion network as an accessible, non-invasive alternative. We used pseudo-continuous arterial spin labelling to measure cerebral grey matter perfusion in 61 subjects with Parkinson's disease with a range of motor and cognitive impairment, including patients with dementia and 29 age- and sex-matched controls. Principal component analysis was used to derive a Parkinson's disease-related perfusion network via logistic regression. Region of interest analysis of absolute perfusion values revealed that the Parkinson's disease pattern was characterized by decreased perfusion in posterior parieto-occipital cortex, precuneus and cuneus, and middle frontal gyri compared with healthy controls. Perfusion was preserved in globus pallidus, putamen, anterior cingulate and post- and pre-central gyri. Both motor and cognitive statuses were significant factors related to network score. A network approach, supported by arterial spin labelling-derived absolute perfusion values may provide a readily accessible neuroimaging method to characterize and track progression of both motor and cognitive status in Parkinson's disease. [ABSTRACT FROM AUTHOR]

Published
2011
Full Text
View/download PDF

20. Effects of acute tryptophan depletion on neuropsychological and motor function in Parkinson’s disease.

Author

Mace, JL, Porter, RJ, Dalrymple-Alford, JC, Wesnes, KA, and Anderson, TJ

Abstract

Interactions between the 5-HT system and the dopaminergic system and cholinergic system may be important in determining cognitive function and motor function in Parkinson’s disease (PD). Previous studies have shown effects of reducing serotonin function, by acute tryptophan depletion (ATD), on neuropsychological function. In particular, an adverse effect on verbal memory has been demonstrated. This study compared with the effects of ATD on cognitive and motor function in PD and healthy control subjects. The effects of ATD were investigated in a double-blind, placebo-controlled, counterbalanced, cross-over, randomised design in 20 patients with PD and 35 healthy controls matched for age, gender and premorbid IQ. There was a differential group effect of ATD on global cognitive function whereby the mean score on the modified mini mental state examination during ATD was lower than placebo in PD but higher in controls. There was a similar pattern of effects on verbal recognition. In a visual recognition task, ATD improved performance in the PD but not in the control group. In terms of psychomotor speed, there was also a group-specific effect with reduced latency of response during ATD in the PD group but increased latency in the control group. ATD has subtle neuropsychological effects, which differ significantly between PD and healthy control subjects. This suggests that the dopaminergic and cholinergic deficit of PD significantly modulates the effects of serotonin depletion, resulting in positive effects in some domains. Further investigation on the effects of specific serotonin antagonists may be merited in PD. [ABSTRACT FROM PUBLISHER]

Published
2010
Full Text
View/download PDF

25. Effect of chelation therapy on endothelial function in patients with coronary artery disease: PATCH substudy.

Author

Anderson TJ, Hubacek J, Wyse DG, Knudtson ML, Anderson, Todd J, Hubacek, Jaroslav, Wyse, D George, and Knudtson, Merril L

Abstract

Objectives: The purpose of this study was to evaluate the effect of chelation therapy with ethylenediamine tetraacetic acid (EDTA) on endothelium-dependent vasomotor responses in patients with documented coronary artery disease (CAD).Background: Oxidative stress plays an important role in the dysfunction of endothelium and development of atherosclerosis. Modification of cardiac risk factors and employment of antioxidants have been shown to improve endothelial function. Ethylenediamine tetraacetic acid chelation therapy is considered to be a complementary therapy for patients with CAD and is proposed to have antioxidant properties.Methods: A total of 47 patients enrolled in the Program to Assess Alternative Treatment Strategies to Achieve Cardiac Health (PATCH) participated in this substudy and had complete data. High-resolution ultrasound was used to assess endothelium-dependent brachial artery flow-mediated vasodilation (FMD) in patients with CAD in a randomized, double-blind, and placebo-controlled fashion. Patients were randomized to chelation therapy or placebo. The primary end point was the absolute difference in FMD after the first and 33rd treatments (6 months) of study groups compared with their baselines.Results: At the baseline, the study population had mild impairment of FMD (7.2 +/- 3.4%). The first chelation treatment did not change FMD as compared with placebo (chelation 6.5 +/- 3.5% vs. placebo 7.4 +/- 2.9%; p value = 0.371). The brachial artery studies at six months did not demonstrate significant differences in FMD between study groups (placebo 7.3 +/- 3.4% vs. chelation 7.3 +/- 3.2%; p value = 0.961).Conclusions: Our results suggest that EDTA chelation therapy in combination with vitamins and minerals does not provide additional benefits on abnormal vasomotor responses in patients with CAD optimally treated with proven therapies for atherosclerotic risk factors. [ABSTRACT FROM AUTHOR]

Published
2003
Full Text
View/download PDF

26. Guidelines for the ultrasound assessment of endothelial-dependent flow-mediated vasodilation of the brachial artery: a report of the International Brachial Artery Reactivity Task Force [corrected] [published erratum appears in J AM COLL CARDIOL 2002 Mar 20;39(6):1082].

Author

Corretti MC, Anderson TJ, Benjamin EJ, Celermajer D, Charbonneau F, Creager MA, Deanfield J, Drexler H, Gerhard-Herman M, Herrington D, Vallance P, Vita J, Vogel R, Corretti, Mary C, Anderson, Todd J, Benjamin, Emelia J, Celermajer, David, Charbonneau, Francois, Creager, Mark A, and Deanfield, John

Abstract

Endothelial function is thought to be an important factor in the pathogenesis of atherosclerosis, hypertension and heart failure. In the 1990s, high-frequency ultrasonographic imaging of the brachial artery to assess endothelium-dependent flow-mediated vasodilation (FMD) was developed. The technique provokes the release of nitric oxide, resulting in vasodilation that can be quantitated as an index of vasomotor function. The noninvasive nature of the technique allows repeated measurements over time to study the effectiveness of various interventions that may affect vascular health. However, despite its widespread use, there are technical and interpretive limitations of this technique. State-of-the-art information is presented and insights are provided into the strengths and limitations of high-resolution ultrasonography of the brachial artery to evaluate vasomotor function, with guidelines for its research application in the study of endothelial physiology. [ABSTRACT FROM AUTHOR]

Published
2002
Full Text
View/download PDF

41. Projected sensitivity of the LUX-ZEPLIN experiment to the 0νββ decay of 136Xe

Author

Akerib, DS, Akerlof, CW, Alqahtani, A, Alsum, SK, Anderson, TJ, Angelides, N, Araújo, HM, Armstrong, JE, Arthurs, M, Bai, X, Balajthy, J, Balashov, S, Bang, J, Baxter, A, Bensinger, J, Bernard, EP, Bernstein, A, Bhatti, A, Biekert, A, Biesiadzinski, TP, Birch, HJ, Boast, KE, Boxer, B, Brás, P, Buckley, JH, Bugaev, VV, Burdin, S, Busenitz, JK, Cabrita, R, Carels, C, Carlsmith, DL, Benitez, MCC, Cascella, M, Chan, C, Chott, NI, Cole, A, Cottle, A, Cutter, JE, Dahl, CE, Viveiros, LD, Dobson, JEY, Druszkiewicz, E, Edberg, TK, Eriksen, SR, Fan, A, Fiorucci, S, Flaecher, H, Fraser, ED, Fruth, T, Gaitskell, RJ, Genovesi, J, Ghag, C, Gibson, E, Gilchriese, MGD, Gokhale, S, Grinten, MGDVD, Hall, CR, Harrison, A, Haselschwardt, SJ, Hertel, SA, Hor, JYK, Horn, M, Huang, DQ, Ignarra, CM, Jahangir, O, Ji, W, Johnson, J, Kaboth, AC, Kamaha, AC, Kamdin, K, Kazkaz, K, Khaitan, D, Khazov, A, Khurana, I, Kocher, CD, Korley, L, Korolkova, EV, Kras, J, Kraus, H, Kravitz, S, Kreczko, L, Krikler, B, Kudryavtsev, VA, Leason, EA, Lee, J, Leonard, DS, Lesko, KT, Levy, C, Li, J, Liao, J, Liao, FT, Lin, J, Lindote, A, Linehan, R, Lippincott, WH, Liu, R, Liu, X, Loniewski, C, Lopes, MI, Paredes, BL, Lorenzon, W, Luitz, S, Lyle, JM, Majewski, PA, Manalaysay, A, Manenti, L, Mannino, RL, Marangou, N, Marzioni, MF, McKinsey, DN, McLaughlin, J, Meng, Y, Miller, EH, Mizrachi, E, Monte, A, Monzani, ME, Morad, JA, Morrison, E, Mount, BJ, Murphy, ASJ, Naim, D, Naylor, A, Nedlik, C, Nehrkorn, C, Nelson, HN, Neves, F, Nikoleyczik, JA, Nilima, A, O'Sullivan, K, Olcina, I, Oliver-Mallory, KC, Pal, S, Palladino, KJ, Palmer, J, Parveen, N, Pease, EK, Penning, B, Pereira, G, Pushkin, K, Reichenbacher, J, Rhyne, CA, Riffard, Q, Rischbieter, GRC, Rosero, R, Rossiter, P, Rutherford, G, Santone, D, Sazzad, ABMR, Schnee, RW, Schubnell, M, Seymour, D, Shaw, S, Shutt, TA, Silk, JJ, Silva, C, Smith, R, Solmaz, M, Solovov, VN, Sorensen, P, Stancu, I, Stevens, A, Stifter, K, Sumner, TJ, Swanson, N, Szydagis, M, Tan, M, Taylor, WC, Taylor, R, Temples, DJ, Terman, PA, Tiedt, DR, Timalsina, M, Tomás, A, Tripathi, M, Tronstad, DR, Turner, W, Tvrznikova, L, Utku, U, Vacheret, A, Vaitkus, A, Wang, JJ, Wang, W, Watson, JR, Webb, RC, White, RG, Whitis, TJ, Wolfs, FLH, Woodward, D, Xiang, X, Xu, J, Yeh, M, and Zarzhitsky, P

Abstract

The LUX-ZEPLIN (LZ) experiment will enable a neutrinoless double beta decay search in parallel to the main science goal of discovering dark matter particle interactions. We report the expected LZ sensitivity to ^136Xe neutrinoless double beta decay, taking advantage of the significant (>600 kg) ^136Xe mass contained within the active volume of LZ without isotopic enrichment. After 1000 live-days, the median exclusion sensitivity to the half-life of ^136Xe is projected to be 1.06×10^26 years (90% confidence level), similar to existing constraints. We also report the expected sensitivity of a possible subsequent dedicated exposure using 90% enrichment with ^136Xe at 1.06×10^27 years.

Catalog

Books, media, physical & digital resources
See catalog results